New pill combo shows promise against resistant lung cancer
NCT ID NCT05015608
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether combining two targeted drugs, savolitinib and osimertinib, works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and has stopped responding to initial treatment. The trial enrolled 216 adults and measured how long the cancer stayed under control. The goal is to find a more effective, less toxic option for these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Savolitinib and Osimertinib (oral drugs)
- What this could lead to
- If successful, this combination could offer a new targeted treatment option for people with a specific type of lung cancer that has stopped responding to initial therapy.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet widely known. The combination may not prove more effective than standard chemotherapy and could have side effects like nausea, fatigue, or liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH MET AMPLIFICATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?